Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy
Epilepsia · 2024
DOI: 10.1111/epi.17873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Matthias Hentschel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Nitriles, Pyridones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The aim of this study was to determine whether clinical efficacy and reported adverse effects (AEs) of the newer antiseizure medications (ASMs) brivaracetam (BRV), lacosamide (LCM), and perampanel (PER) have been associated with plasma levels of these ASMs. We also investigated whether plasma levels outside the reference range has led to dose adjustments.
Methods
Plasma levels of 300 people with epilepsy (PWE) seen at our tertiary epilepsy center were determined by liquid chromatography–tandem mass spectrometry. PWE received BRV ( n = 100), LCM ( n = 100), or PER ( n = 100), in most cases in polytherapy. Demographic and clinical data were retrospectively analyzed and related to plasma levels. Clinical efficacy of BRV, LCM, or PER was assessed retrospectively by comparing seizure frequency at the time of current blood draw with seizure frequency at the time of first administration. AEs were also recorded and, if reported, compared retrospectively with the time of first administration.
Results
No significant associations were found between plasma levels of BRV, LCM, or PER and seizure freedom (BRV, p = 1.000; LCM, p = .243; PER, p = .113) or responder status (BRV, p = .118; LCM, p = .478; PER, p = .069) at presentation. There was also no pattern between plasma levels and the occurrence of AEs. In the majority of cases, drug levels outside the reference ranges have not led to adjustments in the daily doses of BRV (93.5%), LCM (93.9%), or PER (89.1%). Significance Plasma levels at a given time point did not allow conclusions to be drawn about seizure control or the occurrence of AEs. Our findings indicate that efficacy and tolerability cannot be predicted based on averaged data from a single plasma measurement due to high interindividual variability. Instead, individual reference values should be established when sufficient clinical data are available, in line with the 2008 International League Against Epilepsy position paper on therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
- Department of Epileptology, University Hospital Bonn, Bonn, Germany.
ORCID-Profile: Matthias Hentschel, Randi von Wrede
Zitieren
APA
Hentschel, M., Stoffel-Wagner, B., Surges, R., von Wrede, R., & Dolscheid-Pommerich, R. C. (2024). Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy. Epilepsia. https://doi.org/10.1111/epi.17873
Vancouver
Hentschel M, Stoffel-Wagner B, Surges R, von Wrede R, Dolscheid-Pommerich RC. Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy. Epilepsia. 2024. doi:10.1111/epi.17873
BibTeX
@article{Hentschel2024,
author = {Hentschel, Matthias and Stoffel-Wagner, Birgit and Surges, Rainer and von Wrede, Randi and Dolscheid-Pommerich, Ramona Christina},
title = {Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.17873}
}
EUVIMED